Sir, Patient satisfaction in the Peterborough community specialist optometrist in glaucoma shared-care scheme
We note with interest the results published by Levy and Booth 1 on 'Patient satisfaction with Peninsula Optometry Community Glaucoma Scheme'. We have significant experience with our own community optometrist glaucoma scheme 2 and have recently collected satisfaction data.
Questionnaires were sent to 120 patients attending the community scheme and 120 patients in the hospital glaucoma service. Patients were questioned about the clinician they saw, and their satisfaction with the service overall (Table 1) . Response rate was 57%.
Patients in the community scheme were asked whether they would like to continue with the scheme, whereas patients in the hospital service were asked if they would be happy to be transferred to the community scheme. Sixty-two out of 66 patients in the community scheme were happy to remain, whereas only 33/65 of hospital patients would be happy to be transferred to the community optometrist scheme. The difference in satisfaction between the optometrist and doctor may reflect differences in training (with a more client-oriented approach in optometry) or differences in perceived time pressures. Satisfaction rates were equivalent between the schemes overall.
Both previous publications on satisfaction in community schemes found higher satisfaction with the community service, whereas we have found them equivalent. In comparison with the Bristol scheme, 3 we did not randomise our patients to each group, and therefore some of the hospital patients may have been ineligible for the community scheme. In contrast to Levy and Booth's 1 series, we asked patients to comment on satisfaction with their current scheme, rather than making a comparison.
Patients in the scheme were happy to remain there, whereas of those in the hospital only half would be happy to be transferred. This may be due to more complicated requirements (whether perceived or real) of the hospital patients' glaucoma. Without adequate explanation, the patient may feel that they are being 'downgraded' or outsourced. We would like to highlight the importance of adequate information given to patients when they are transferred to a community scheme. It is difficult to overestimate the importance of the UK National Health Service (NHS) policy to structurally assess the cost effectiveness of novel treatments. This policy serves as an example for policy makers in many developed countries, and the outcomes of the analyses are made available to fellow researchers in the field. The recent publication by Salmon et al 1 regarding the cost effectiveness of crosslinking for progressive keratoconus is an excellent example of this. The authors concluded that crosslinking is likely to be cost effective, with an incremental cost of £3174 per quality-adjusted life year (QALY), supporting the NHS' decision to reimburse this treatment.
We would like to address the methods used in this study, specifically the authors' calculation of QALYs in keratoconus. QALYs represent the value of the impact of disease on quality of life measured over a lifetime. The concept is based on the measurement of utilities. A utility is represented on a scale anchored at 0 (representing death) and 1 (representing full health) and can be assessed using specific questionnaires (eg, the Euroqol EQ-5D (Euroqol group http://www.euroqol.org/about-eq-5d. html)) or calculated from patient-reported health surveys (eg, SF-6D 2 derived from Short From 36 Health (SF-36) survey questionnaires 3 ). QALYs and utilities are the preferred outcome measures used when performing a cost effectiveness analysis. The authors state that direct measures of utilities in keratoconus are not available and therefore estimated utilities based on expected visual acuity (VA) in various stages of keratoconus, leading to decreased utilities in advanced keratoconus.
However, the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) study measured SF-36 in more than 1200 keratoconus patients, including appropriate descriptions of the patients' VA, keratometry, and subsequent staging using the Amsler-Krumeich classification. 4 Using the CLEK database, we classified all of the included subjects according to their keratometry readings, and we linked these results to SF-6D-derived utilities, following the method developed by Brazier et al. 2 
